Dr. Reddy’s Laboratories Limited, a global pharmaceutical company based in Hyderabad, India, disclosed in a recent securities filing that the U.S. Department of Justice had closed an investigation into possible violations of the Foreign Corrupt Practices Act (“FCPA”) by the company. According to Exhibit 99.1 of a Form 6-K filed by Dr. Reddy’s on March 6, 2026, the company received a letter dated March 5, 2026, that stated that the Fraud Section of the DOJ’s Criminal Division had chosen to close its investigation based on information available to it, without recommending an enforcement action.
According to the 6-K, Dr. Reddy’s launched an investigation after receiving an anonymous complaint regarding improper payments made to healthcare professionals in Ukraine and possibly other jurisdictions that may have violated U.S. anti-corruption laws, including the FCPA. The company stated that it had engaged a U.S. law firm to investigate the allegations and that it had self-disclosed the matter to the DOJ, the U.S. Securities and Exchange Commission, and the Securities Exchange Board of India (“SEBI”).
The 6-K also noted that the SEC recently informed Dr. Reddy’s, in a letter dated February 23, 2026, that it had concluded a related investigation into the company with no intention to recommend an enforcement action at the time. The company did not provide any information regarding the status of the SEBI’s investigation.